RIADE, Arábia Saudita, March 26, 2024 (GLOBE NEWSWIRE) — Em um desenvolvimento revolucionário, cientistas do King Faisal Specialist Hospital and Research Centre (KFSH&RC) identificaram uma [...] Read more »
Im Rahmen der weltweiten Bemühungen zur Bekämpfung antibiotikaresistenter Bakterien entdecken KFSH&RC‑Wissenschaftler die neue Bakterienspezies: Riyadhensis
RIAD, Saudi–Arabien, March 26, 2024 (GLOBE NEWSWIRE) — In einer bahnbrechenden Entwicklung haben Wissenschaftler des King Faisal Specialist Hospital and Research Centre (KFSH&RC) durch [...] Read more »
Les scientifiques de l’hôpital spécialisé et centre de recherche King Faisal contribuent aux efforts internationaux de lutte contre l’antibiorésistance des bactéries en identifiant une toute nouvelle espèce de bactérie : Riyadhensis
RIYAD, Arabie saoudite, 26 mars 2024 (GLOBE NEWSWIRE) — Des scientifiques de l’hôpital spécialisé et centre de recherche King Faisal (ou [...] Read more »
To Bolster Global Efforts in Combating Antibiotic-Resistant Bacteria KFSH&RC Scientists Discover New Bacteria Species: Riyadhensis
RIYADH, Saudi Arabia, March 25, 2024 (GLOBE NEWSWIRE) — In a ground–breaking development, scientists at King Faisal Specialist Hospital and Research Centre (KFSH&RC) have identified a [...] Read more »
لتعزيز الجهود العالمية لمكافحة البكتيريا المقاومة للمضادات الحيوية علماء في التخصصي .. يكتشفون نوعاً جديداً من البكتيريا باسم “رياض نسيس”
الرياض, March 25, 2024 (GLOBE NEWSWIRE) —
اكتشف [...] Read more »
Blue California completes groundbreaking human clinical trial on ErgoActive® ergothioneine intervention for cognitive function, memory, and sleep
Rancho Santa Margarita, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) — Read more »
Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis
JERUSALEM, Nov. 09, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, reports [...] Read more »
King Faisal Specialist Hospital and Research Centre Lança Inovadora Farmacogenômica Clínica
RIADE, Arábia Saudita, Oct. 25, 2023 (GLOBE NEWSWIRE) — O King Faisal Specialist Hospital and Research Centre (KFSH&RC) tem o orgulho de anunciar o lanamento da fase inaugural do seu servio de farmacogenmica [...] Read more »
King Faisal Specialist Hospital and Research Centre gibt Start des innovativen klinischen Pharmakogenomik-Dienstes bekannt
RIAD, Saudi–Arabien, Oct. 25, 2023 (GLOBE NEWSWIRE) — The King Faisal Specialist Hospital and Research Centre (KFSH&RC) ist stolz darauf, den Start der ersten Phase seines klinischen [...] Read more »
Le King Faisal Specialist Hospital & Research Center annonce le lancement d’un service de pharmacogénomique clinique innovant
RIYADH, Arabie saoudite, 25 oct. 2023 (GLOBE NEWSWIRE) — Le King Faisal Specialist Hospital and Research Centre ( KFSH&RC ) est fier d'annoncer le lancement de la phase inaugurale de son service de [...] Read more »
King Faisal Specialist Hospital and Research Centre Announces Innovative Clinical Pharmacogenomics
RIYADH, Saudi Arabia, Oct. 24, 2023 (GLOBE NEWSWIRE) — The King Faisal Specialist Hospital and Research Centre (KFSH&RC) is proud to announce the launch of the inaugural phase of its clinical pharmacogenomics [...] Read more »
Datacubed Health Launches eClinical Platform App in China, Ensuring Full Compliance and Accessibility
New York, New York, Sept. 26, 2023 (GLOBE NEWSWIRE) — Read more »
Purdue researcher awarded $1.3 million for malaria drug trials in Southeast Asia and Africa
WEST LAFAYETTE, Ind., Sept. 15, 2023 (GLOBE NEWSWIRE) — A Purdue researcher is taking a giant leap forward in the fight against drug–resistant strains of malaria in developing countries.
A Curia apoia o ensaio clínico de fase 1 da nova vacina de RNA de última geração da Replicate Bioscience
ALBANY, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) — A Curia, uma organizao lder em pesquisa, desenvolvimento e fabricao por contrato, anunciou hoje que sua parceira, Replicate Bioscience, recebeu autorizao IND da FDA e dosou o primeiro [...] Read more »
Curia unterstützt die klinische Studie der Phase 1 von Replicate Bioscience mit einem neuartigen RNA-Impfstoff der nächsten Generation
ALBANY, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) — Curia, ein fhrendes Auftragsforschungs–, Entwicklungs– und Produktionsunternehmen, gab heute bekannt, dass sein Partner Replicate Bioscience die IND–Freigabe von der [...] Read more »